Harnessing pandemonium: The clinical implications of tumor heterogeneity in ovarian cancer

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Blagden, Sarah P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chemotherapy resistance; Clonal evolution; Diversity; Heterogeneity; HGSOC; ITH; Ovarian cancer; Tumor evolution

Indexed keywords

EID: 84934295552     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00149     Document Type: Review

References (56)

1. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2010) 1805:105-17. doi: 10.1016/j.bbcan.2009.11.002.
2. Nowell PC. The clonal evolution of tumor cell populations. Science (1976) 194:23-8. doi:10.1126/science.959840.
3. Iscove NN, Senn JS, Till JE, McCulloch EA. Colony formation by normal and leukemic human marrow cells in culture: effect of conditioned medium from human leukocytes. Blood (1971) 37:1-5.
4. Tomasson MH. Cancer stem cells: a guide for skeptics. J Cell Biochem (2009) 105:745-9. doi:10.1002/jcb.22050.
5. Polyak K, Marusyk A. Cancer: clonal cooperation. Nature (2014) 508:52-3. doi:10.1038/508052a.
6. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14:275-91. doi:10.1016/j.stem.2014.02.006.
7. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 12:487-93. doi:10.1038/nrc3298.
8. Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res (1978) 38:3758-63.
9. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 300:762-5. doi:10.1038/300762a0.
10. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature (2001) 409:860-921. doi:10.1038/35057062.
11. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science (2001) 291:1304-51. doi:10.1126/science.1058040.
12. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature (2004) 431:931-45. doi:10.1038/nature03001.
13. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer (2004) 4:177-83. doi:10.1038/nrc1299.
14. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science (2007) 318:1108-13. doi:10.1126/science.1145720.
15. Wheeler DA, Wang L. From human genome to cancer genome: the first decade. Genome Res (2013) 23:1054-62. doi:10.1101/gr.157602.113.
16. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339:1546-58. doi:10.1126/science.1235122.
17. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 12:236-44. doi:10.1016/S1470-2045(11)70033-X.
18. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 467:596-9. doi:10.1038/nature09454.
19. Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol (2008) 20:104-11. doi:10.1097/CCO.0b013e3282f44b12.
20. Teplinsky E, Muggia F. Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecol Oncol (2014) 135:364-70. doi:10.1016/j.ygyno.2014.09.003.
21. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell (2015) 27:15-26. doi:10.1016/j.ccell.2014.12.001.
22. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet (2005) 161:170-3. doi:10.1016/j.cancergencyto.2004.12.014.
23. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 34:433-43. doi:10.1097/PAS.0b013e3181cf3d79.
24. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast Jr, et al. Growth regulation and transformation of ovarian epithelium. Cancer (1993) 71:545-51. doi:10.1002/cncr.2820710209.
25. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology (2013) 45:229-42. doi:10.1097/PAT.0b013e32835f2264.
26. Seidman JD, Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med (2008) 132:1753-60. doi:10.1043/1543-2165-132.11.1753.
27. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 25:3985-90. doi:10.1200/JCO.2007.12.2622.
28. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol (2007) 31:161-9. doi:10.1097/01.pas.0000213335.40358.47.
29. Chene G, Lamblin G, Le Bail-Carval K, Chabert P, Bakrin N, Mellier G. Early preinvasive lesions in ovarian cancer. Biomed Res Int (2014):639252. doi:10.1155/2014/639252.
30. Zeppernick F, Meinhold-Heerlein I, Shih IeM. Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma-an update. J Obstet Gynaecol Res (2015) 41:6-11. doi:10.1111/jog.12550.
31. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 108:168-73. doi:10.1016/j.ygyno.2008.01.012.
32. Sirachỳ J. An approach to the problem of heterogeneity of human tumour-cell populations. Br J Cancer (1979) 39:570-7. doi:10.1038/bjc.1979.103.
33. Ehlen T, Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene (1990) 5:219-23.
34. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res (1990) 50:2724-8.
35. Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, et al. Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res (2003) 63:8648-55.
36. Rhei E, Bogomolniy F, Federici MG, Maresco DL, Offit K, Robson ME, et al. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res (1998) 58:3193-6.
37. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res (1991) 51(19):5171-6.
38. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 211:286-95. doi:10.1002/path.2112.
39. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C. Mutational landscape and significance across 12 major cancer types. Nature (2013) 502:333-9. doi:10.1038/nature12634.
40. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474:609-15. doi:10.1038/nature10166.
41. Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, et al. Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One (2011) 6:e28561. doi:10.1371/journal.pone.0028561.
42. McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, Butler A, et al. Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol (2012) 227:446-55. doi:10.1002/path.4042.
43. McNeish IA, Oza AM, Coleman RL, Scott CL, Konecny GE, Tinker A, et al. Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol (2015) 33(Suppl):abstr5508.
44. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 14:5198-208. doi:10.1158/1078-0432.CCR-08-0196.
45. Leong HS, Galletta L, Etemadmoghadam D, George J, Australian Ovarian Cancer Study, Köbel M, et al. Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol (2015) 236:272-7. doi:10.1002/path.4536.
46. Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, et al. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol (2013) 231:424-32. doi:10.1002/path.4284.
47. Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J, Williamson DW, Carlson CS, et al. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol (2013) 231:433-40. doi:10.1002/path.4260.
48. Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, et al. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res (2014) 24:200-11. doi:10.1101/gr.161026.113.
49. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 467:1109-13. doi:10.1038/nature09460.
50. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366:883-92. doi:10.1056/NEJMoa1113205.
51. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 231:21-34. doi:10.1002/path.4230.
52. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 72:4875-82. doi:10.1158/0008-5472.CAN-12-2217.
53. Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Phylogenetic quantification of intra-tumor heterogeneity predicts time to relapse in high-grade serous ovarian cancer. PLoS Med (2015) 12:e1001789. doi:10.1371/journal.pmed.1001789.
54. Hayes DF, Paoletti C. Circulating tumour cells: insights into tumour heterogeneity. J Intern Med (2013) 274(2):137-43. doi:10.1111/joim.12047.
55. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 497:108-12. doi:10.1038/nature12065.
56. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 346:251-6. doi:10.1126/science.1253462.